About Us

Depomed – Enhancing Pharmaceuticals

Depomed, Inc. (Nasdaq: DEPO) is a specialty pharmaceutical company focused on enhancing pharmaceutical products. Since its founding in August 1995, the company has advanced two products to market and has developed a pipeline with late-stage product opportunities intended to address common medical conditions affecting large patient populations.

The AcuForm Advantage

At the core of Depomed is AcuForm™ delivery technology, a unique, patented, polymer-based technology designed to optimize drug delivery through gastric retention. AcuForm technology allows for targeted, extended release of pharmaceutical ingredients to the upper gastrointestinal tract, which allows for increased bioavailability, less frequent dosing, and fewer side effects than seen with other formulations.  Improvements made possible with AcuForm hold the potential to provide proven compounds with NCE-like differentiation.

Company Strategy

Depomed’s strategy is to develop and play an active role in the commercialization of AcuForm-enhanced formulations of proven, well-characterized oral drugs that address large patient populations. To accomplish this, the company works independently as well as in partnership with companies that share this goal.